3-[[(3aR,5R,6S,7S,7aR)-6,7-dihydroxy-3-(2-hydroxyphenyl)-2-oxo-5,6,7,7a-tetrahydro-3aH-pyrano[2,3-d][1,3]oxazol-5-yl]methoxy]-3-oxopropanoic acid
| Internal ID | 438110ed-1ef8-4b9e-a143-d20b0c9c6e85 |
| Taxonomy | Benzenoids > Phenols > 1-hydroxy-4-unsubstituted benzenoids |
| IUPAC Name | 3-[[(3aR,5R,6S,7S,7aR)-6,7-dihydroxy-3-(2-hydroxyphenyl)-2-oxo-5,6,7,7a-tetrahydro-3aH-pyrano[2,3-d][1,3]oxazol-5-yl]methoxy]-3-oxopropanoic acid |
| SMILES (Canonical) | C1=CC=C(C(=C1)N2C3C(C(C(C(O3)COC(=O)CC(=O)O)O)O)OC2=O)O |
| SMILES (Isomeric) | C1=CC=C(C(=C1)N2[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)CC(=O)O)O)O)OC2=O)O |
| InChI | InChI=1S/C16H17NO10/c18-8-4-2-1-3-7(8)17-15-14(27-16(17)24)13(23)12(22)9(26-15)6-25-11(21)5-10(19)20/h1-4,9,12-15,18,22-23H,5-6H2,(H,19,20)/t9-,12-,13+,14-,15-/m1/s1 |
| InChI Key | UBNYULGLIGRDSX-SWMGHYKJSA-N |
| Popularity | 0 references in papers |
| Molecular Formula | C16H17NO10 |
| Molecular Weight | 383.31 g/mol |
| Exact Mass | 383.08524574 g/mol |
| Topological Polar Surface Area (TPSA) | 163.00 Ų |
| XlogP | -0.60 |
| Atomic LogP (AlogP) | -0.82 |
| H-Bond Acceptor | 9 |
| H-Bond Donor | 4 |
| Rotatable Bonds | 5 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.7408 | 74.08% |
| Caco-2 | - | 0.7807 | 78.07% |
| Blood Brain Barrier | - | 0.5750 | 57.50% |
| Human oral bioavailability | - | 0.6429 | 64.29% |
| Subcellular localzation | Mitochondria | 0.5098 | 50.98% |
| OATP2B1 inhibitior | - | 0.8528 | 85.28% |
| OATP1B1 inhibitior | + | 0.8897 | 88.97% |
| OATP1B3 inhibitior | + | 0.9361 | 93.61% |
| MATE1 inhibitior | - | 0.9400 | 94.00% |
| OCT2 inhibitior | - | 0.9110 | 91.10% |
| BSEP inhibitior | - | 0.6340 | 63.40% |
| P-glycoprotein inhibitior | - | 0.7807 | 78.07% |
| P-glycoprotein substrate | - | 0.8807 | 88.07% |
| CYP3A4 substrate | + | 0.5341 | 53.41% |
| CYP2C9 substrate | - | 0.8030 | 80.30% |
| CYP2D6 substrate | - | 0.8125 | 81.25% |
| CYP3A4 inhibition | - | 0.8979 | 89.79% |
| CYP2C9 inhibition | - | 0.8589 | 85.89% |
| CYP2C19 inhibition | - | 0.8492 | 84.92% |
| CYP2D6 inhibition | - | 0.8393 | 83.93% |
| CYP1A2 inhibition | - | 0.7932 | 79.32% |
| CYP2C8 inhibition | - | 0.7226 | 72.26% |
| CYP inhibitory promiscuity | - | 0.9525 | 95.25% |
| UGT catelyzed | + | 0.7000 | 70.00% |
| Carcinogenicity (binary) | - | 0.9500 | 95.00% |
| Carcinogenicity (trinary) | Non-required | 0.4956 | 49.56% |
| Eye corrosion | - | 0.9880 | 98.80% |
| Eye irritation | - | 0.7858 | 78.58% |
| Skin irritation | - | 0.7988 | 79.88% |
| Skin corrosion | - | 0.9415 | 94.15% |
| Ames mutagenesis | - | 0.5400 | 54.00% |
| Human Ether-a-go-go-Related Gene inhibition | - | 0.6892 | 68.92% |
| Micronuclear | + | 0.9200 | 92.00% |
| Hepatotoxicity | + | 0.5888 | 58.88% |
| skin sensitisation | - | 0.8809 | 88.09% |
| Respiratory toxicity | + | 0.7444 | 74.44% |
| Reproductive toxicity | + | 0.9667 | 96.67% |
| Mitochondrial toxicity | + | 0.8125 | 81.25% |
| Nephrotoxicity | - | 0.7166 | 71.66% |
| Acute Oral Toxicity (c) | III | 0.6741 | 67.41% |
| Estrogen receptor binding | + | 0.7010 | 70.10% |
| Androgen receptor binding | - | 0.6962 | 69.62% |
| Thyroid receptor binding | - | 0.6805 | 68.05% |
| Glucocorticoid receptor binding | - | 0.5234 | 52.34% |
| Aromatase binding | - | 0.5554 | 55.54% |
| PPAR gamma | + | 0.5531 | 55.31% |
| Honey bee toxicity | - | 0.9198 | 91.98% |
| Biodegradation | - | 0.6250 | 62.50% |
| Crustacea aquatic toxicity | - | 0.7900 | 79.00% |
| Fish aquatic toxicity | + | 0.9392 | 93.92% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 97.38% | 91.11% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 94.35% | 96.09% |
| CHEMBL2581 | P07339 | Cathepsin D | 92.06% | 98.95% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 91.19% | 83.82% |
| CHEMBL2345 | P51812 | Ribosomal protein S6 kinase alpha 3 | 89.27% | 95.64% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 88.95% | 90.17% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 86.69% | 95.56% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 86.32% | 99.23% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 85.88% | 89.00% |
| CHEMBL2035 | P08912 | Muscarinic acetylcholine receptor M5 | 82.09% | 94.62% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 80.86% | 86.33% |
| PubChem | 11617890 |
| LOTUS | LTS0266063 |
| wikiData | Q105269517 |